OUR MISSION - to evaluate and establish the role of innate immunity in fighting cancer and treating autoimmune diseases.
The Company’s lead product, Vesimune (TMX-101), is currently in clinical development for the localised treatment of bladder cancer, a disease of unmet medical need. The second product, TMX-202, is in preclinical trials for topical treatments for skin and bladder cancers and a third product, TMX-201, is in development for use as a vaccine adjuvant. Telormedix also has an additional pipeline of programmes for autoimmune diseases; the main product in this pipeline is called TMX-302. Founded in October 2007, Telormedix is located in Switzerland and is led by a highly experienced management team and backed by a consortium of leading global investors.